

ALLERGAN INC
Form 424B3
April 04, 2003

PROSPECTUS SUPPLEMENT NO. 9
(TO PROSPECTUS DATED JANUARY 21, 2003)

\$641,510,000
ALLERGAN, INC.

ZERO COUPON CONVERTIBLE SENIOR NOTES DUE 2022
SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION OF THE NOTES

This Prospectus Supplement No. 9 supplements and amends the Prospectus dated January 21, 2003, as amended (as amended, the Prospectus), relating to the resale from time to time by holders of our Zero Coupon Convertible Senior Notes Due 2022 and shares of our common stock issuable upon the conversion of the notes. Such information has been obtained from the selling securityholders. This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement.

The information appearing in the table below, as of the date hereof, supplements and amends the information in the table appearing under the heading "Selling Securityholders" in the Prospectus, and, where the name of a Selling Securityholder identified in the table below also appears in the table in the Prospectus, the information set forth in the table below regarding that Selling Securityholder supercedes the information in the Prospectus:

NAME	PRINCIPAL AMOUNT OF	PERCENTAGE OF NOTES	COMMON STOCK OWNED	COMMON STOCK OFFERED HEREBY(1)
	NOTES OWNED AND OFFERED HEREBY		PRIOR TO THE OFFERING	
Banc of America Securities LLC(2)	\$4,701,000	1.70%(3)	70,537(4)	53,638
Family Service Life Insurance Co.	\$ 400,000	*		4,564
Guardian Life Insurance Co.	\$7,300,000	1.14%		82,293
Guardian Pension Trust	\$1,200,000	*		13,692
Park Avenue Life Insurance Co.	\$ 100,000	*		1,141

* Less than one percent.

(1) The number of shares of common stock offered hereby includes shares of common stock into which the notes are convertible. The number of shares of common stock offered hereby is based on a conversion rate of 11.410 shares of common stock per \$1,000 principal amount of maturity of the

notes.
Information
concerning
other Selling
Securityholders
will be set forth
in prospectus
supplements
from time to
time, if
required. The
number of
shares of
common stock
owned by the
other Selling
Securityholders
or any future
transferee from
any such holder
assumes that
they do not
beneficially
own any
common stock
other than
common stock
into which the
notes are
convertible at a
conversion rate
of 11.410 shares
of common
stock per \$1,000
principal
amount of
maturity of the
notes.(2) Banc
of America
Securities LLC
acted as joint
book-running
manager and
initial purchaser
in connection
with the
issuance by
Allergan of the
notes.(3) Includes
\$6,182,000
principal
amount at
maturity of
previously
acquired
registered
notes.(4) Reflects
shares of
common stock
issuable upon
the conversion
of previously

acquired
registered notes.

INVESTING IN THE NOTES OR THE COMMON STOCK ISSUABLE UPON CONVERSION OF THE NOTES INVOLVES A HIGH DEGREE OF RISK. PLEASE CONSIDER THE RISK FACTORS BEGINNING ON PAGE 7 OF THE PROSPECTUS.

NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THE PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

The date of this prospectus supplement is April 4, 2003.